IL159772A0 - Taxol enhancer compounds - Google Patents
Taxol enhancer compoundsInfo
- Publication number
- IL159772A0 IL159772A0 IL15977202A IL15977202A IL159772A0 IL 159772 A0 IL159772 A0 IL 159772A0 IL 15977202 A IL15977202 A IL 15977202A IL 15977202 A IL15977202 A IL 15977202A IL 159772 A0 IL159772 A0 IL 159772A0
- Authority
- IL
- Israel
- Prior art keywords
- paclitaxel
- compound
- enhancer compounds
- administration
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D8/00—Hair-holding devices; Accessories therefor
- A45D8/004—Hair-holding devices; Accessories therefor with decorative arrangements or form
- A45D8/006—Interchangeable ornaments attached to hair holding devices
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30425201P | 2001-07-10 | 2001-07-10 | |
US36193602P | 2002-03-06 | 2002-03-06 | |
PCT/US2002/021714 WO2003006428A1 (en) | 2001-07-10 | 2002-07-10 | Taxol enhancer compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159772A0 true IL159772A0 (en) | 2004-06-20 |
Family
ID=26973914
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15977202A IL159772A0 (en) | 2001-07-10 | 2002-07-10 | Taxol enhancer compounds |
IL159772A IL159772A (en) | 2001-07-10 | 2004-01-08 | Pharmaceutical preparations containing bis [amide thiohydride-rich], a number of such new compounds and their uses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL159772A IL159772A (en) | 2001-07-10 | 2004-01-08 | Pharmaceutical preparations containing bis [amide thiohydride-rich], a number of such new compounds and their uses |
Country Status (20)
Country | Link |
---|---|
US (4) | US6762204B2 (de) |
EP (2) | EP1406870B1 (de) |
JP (1) | JP4344234B2 (de) |
KR (2) | KR100991325B1 (de) |
CN (1) | CN1308302C (de) |
AT (2) | ATE523194T1 (de) |
AU (1) | AU2002354641B2 (de) |
BR (1) | BR0211228A (de) |
CA (1) | CA2454120C (de) |
DE (1) | DE60234345D1 (de) |
ES (1) | ES2395141T3 (de) |
HK (1) | HK1060117A1 (de) |
IL (2) | IL159772A0 (de) |
IS (1) | IS2718B (de) |
MX (1) | MXPA04000243A (de) |
NO (1) | NO333230B1 (de) |
NZ (1) | NZ530964A (de) |
TW (1) | TWI297335B (de) |
WO (1) | WO2003006428A1 (de) |
ZA (1) | ZA200401054B (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
US6924312B2 (en) | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
HUP0500843A2 (hu) * | 2001-12-20 | 2005-12-28 | Bristol-Myers Squibb Co., | Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények |
AU2006228035B2 (en) * | 2003-01-15 | 2010-02-18 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
TWI330079B (en) * | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
WO2006009940A1 (en) * | 2004-06-23 | 2006-01-26 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
JP5204489B2 (ja) * | 2004-11-19 | 2013-06-05 | シンタ ファーマスーティカルズ コーポレイション | Hsp70発現を増加するためのビス(チオ‐ヒドラジドアミド) |
WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
AU2005232302B2 (en) | 2005-02-14 | 2011-08-18 | Konami Australia Pty Ltd | Gaming Machine with runs of symbols |
JP2008536870A (ja) * | 2005-04-15 | 2008-09-11 | シンタ ファーマシューティカルズ コーポレーション | 治療のためのナチュラルキラー細胞活性増強法 |
US8017654B2 (en) * | 2005-04-15 | 2011-09-13 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
WO2006113493A2 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
MX2007014314A (es) * | 2005-05-16 | 2008-02-11 | Synta Pharmaceuticals Corp | Sintesis de sales de bis(tio-hidrazida amida). |
JP2009504740A (ja) * | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | ビス(チオ−ヒドラジドアミド)製剤 |
US20080176828A1 (en) * | 2006-08-21 | 2008-07-24 | Martin Williams | Treating melanoma with BIS(THIOHYDRAZIDE AMIDES) |
TWI440632B (zh) | 2006-08-21 | 2014-06-11 | Synta Pharmaceuticals Corp | 用於治療增生性疾病的化合物 |
TW200817371A (en) | 2006-08-21 | 2008-04-16 | Synta Pharmaceuticals Corp | Compounds for treating proliferative disorders |
US20100068174A1 (en) * | 2006-08-21 | 2010-03-18 | Synta Pharmaceuticals Corp. | Combination with bis (thiohydrazide amides) for treating cancer |
EP2057118B1 (de) * | 2006-08-21 | 2015-03-04 | Synta Pharmaceuticals Corp. | Verbindungen zur behandlung proliferativer erkrankungen |
US20080226588A1 (en) * | 2006-08-21 | 2008-09-18 | Mcleod Matthew | Treating melanoma with bis(thiohydrazide amides) |
AU2007290490B2 (en) | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
TW200829543A (en) * | 2006-09-15 | 2008-07-16 | Synta Pharmaceuticals Corp | Purification of bis(thiohydrazide amides) |
WO2009020631A2 (en) | 2007-08-07 | 2009-02-12 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
US8618170B2 (en) * | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
WO2009105257A1 (en) * | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
CA2740925A1 (en) | 2008-10-22 | 2010-04-29 | Synta Pharmaceuticals Corp. | Transition metal complexes of a bis[thiohydrazide amide] compound |
EP2349991A4 (de) | 2008-10-22 | 2014-06-04 | Synta Pharmaceuticals Corp | Übergangsmetallkomplexe aus bis[thiohydrazidamid] verbindungen |
US8525776B2 (en) * | 2008-10-27 | 2013-09-03 | Lenovo (Singapore) Pte. Ltd | Techniques for controlling operation of a device with a virtual touchscreen |
US8680100B2 (en) | 2008-12-01 | 2014-03-25 | Synta Pharmaceuticals Corp. | Sulfonylhydrazide compounds for treating proliferative disorders |
US8822532B2 (en) | 2009-12-04 | 2014-09-02 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
US8815945B2 (en) | 2010-04-20 | 2014-08-26 | Masazumi Nagai | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
US20140329892A1 (en) | 2011-11-10 | 2014-11-06 | Synta Pharmaceuticals Corp. | Administration of a bis(thiohydrazide amide) compound for treating cancers |
US20130149392A1 (en) | 2011-12-12 | 2013-06-13 | Synta Pharmaceuticals Corp. | Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
WO2013103795A1 (en) | 2012-01-05 | 2013-07-11 | The Board Of Trustees Of The Leland Stanford Junior University | Bis (thiohydrazide amide) compounds for treating cancers |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3357956A (en) * | 1965-03-30 | 1967-12-12 | Du Pont | Polymeric 1, 3, 4-thiadiazoles and the process for their preparation |
FR2097737A5 (en) | 1970-07-14 | 1972-03-03 | Berlin Chemie Veb | Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4- |
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
GB1272920A (en) | 1971-03-15 | 1972-05-03 | Berlin Chemie Veb | New thiosemicarbazides |
US4012360A (en) * | 1973-12-03 | 1977-03-15 | Ciba-Geigy Corporation | Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines |
JPS5091056A (de) | 1973-12-17 | 1975-07-21 | ||
US4822777A (en) | 1987-02-27 | 1989-04-18 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition |
JP2767241B2 (ja) | 1987-04-15 | 1998-06-18 | ロ−ム アンド ハ−ス コンパニ− | 殺虫性のn−(場合により置換された)−n′−置換−n,n′−ジ置換ヒドラジン |
US6013836A (en) * | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
EP0665818A1 (de) * | 1992-10-23 | 1995-08-09 | Leca Deutschland Gmbh | Offenporige mineralische schüttstoffe mit immobilisierten mikroorganismen, deren herstellung und verwendung |
FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
EP0693924B2 (de) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5840746A (en) | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5523325A (en) | 1993-09-09 | 1996-06-04 | Jacobson; Richard M. | Amidrazones and their use as pesticides |
EP0763014A1 (de) | 1994-06-03 | 1997-03-19 | Basf Aktiengesellschaft | Carbamoylcarbonsäurehydrazide und ihre verwendung zur bekämpfung von schadpilzen |
EP0851874B1 (de) * | 1995-09-22 | 1999-09-15 | Novo Nordisk A/S | Varianten des grünen fluoreszenzproteins, gfp |
US5739686A (en) | 1996-04-30 | 1998-04-14 | Naughton; Michael J. | Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection |
US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
TW479053B (en) * | 1998-10-19 | 2002-03-11 | Agro Kanesho Co Ltd | Hydrazineoxoacetamide derivatives and pesticides |
ES2161594B1 (es) * | 1998-12-17 | 2003-04-01 | Servier Lab | Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
US6322303B1 (en) * | 2000-05-12 | 2001-11-27 | David M. John | Dunnage bag and method of making same |
US7360084B1 (en) * | 2000-05-15 | 2008-04-15 | Nortel Networks Limited | System, device, and method for controlling access in a multicast communication network |
EP1164126A1 (de) * | 2000-06-16 | 2001-12-19 | Basf Aktiengesellschaft | Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen |
US6365745B1 (en) * | 2000-07-14 | 2002-04-02 | Sumika Fine Chemicals Co., Ltd. | Method for producing hydrazine derivative |
US6656971B2 (en) * | 2001-01-25 | 2003-12-02 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
TWI231211B (en) | 2001-05-01 | 2005-04-21 | Abbott Lab | Compositions and methods for enhancing the bioavailability of pharmaceutical agents |
US20040235813A1 (en) | 2001-05-03 | 2004-11-25 | Erich Wanker | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
US6602907B1 (en) * | 2001-06-08 | 2003-08-05 | University Of Central Florida | Treatment of breast cancer |
TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
US6924312B2 (en) * | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
BR0214553A (pt) | 2001-11-28 | 2004-10-13 | Sod Conseils Rech Applic | Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas |
TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
EP1385311B1 (de) * | 2002-07-23 | 2008-05-28 | Matsushita Electric Industrial Co., Ltd. | Endgerät, Kommunikationsmethode und -system zur Authentifizierung von Benutzern in einer Benutzergruppe im Netzwerk |
AU2006228035B2 (en) | 2003-01-15 | 2010-02-18 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
NZ541479A (en) | 2003-02-11 | 2008-11-28 | Vernalis Cambridge Liimited | Isoxazole compounds as inhibitors of heat shock proteins |
KR100575251B1 (ko) | 2003-03-03 | 2006-05-02 | 재단법인서울대학교산학협력재단 | p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법 |
GB2400526B (en) * | 2003-04-08 | 2005-12-21 | Hewlett Packard Development Co | Cryptographic key update management |
EP1493445A1 (de) | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
WO2005046126A1 (en) * | 2003-10-31 | 2005-05-19 | Juniper Networks, Inc. | Secure transport of multicast traffic |
KR100544347B1 (ko) | 2003-12-11 | 2006-01-23 | 한국생명공학연구원 | 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물 |
AU2005230867A1 (en) | 2004-03-26 | 2005-10-20 | Amphora Discovery Corporation | Certain triazole-based compounds, compositions, and uses thereof |
TWI278820B (en) * | 2004-06-07 | 2007-04-11 | Hannstar Display Corp | Impulse driving method and apparatus for liquid crystal device |
WO2006009940A1 (en) | 2004-06-23 | 2006-01-26 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
US20060142393A1 (en) * | 2004-09-16 | 2006-06-29 | Sherman Matthew L | Bis(thio-hydrazide amides) for treatment of hyperplasia |
JP5204489B2 (ja) | 2004-11-19 | 2013-06-05 | シンタ ファーマスーティカルズ コーポレイション | Hsp70発現を増加するためのビス(チオ‐ヒドラジドアミド) |
WO2006062732A2 (en) | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
BRPI0607688A2 (pt) | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto |
JP2008536870A (ja) | 2005-04-15 | 2008-09-11 | シンタ ファーマシューティカルズ コーポレーション | 治療のためのナチュラルキラー細胞活性増強法 |
US8017654B2 (en) | 2005-04-15 | 2011-09-13 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
WO2006113493A2 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
MX2007014314A (es) | 2005-05-16 | 2008-02-11 | Synta Pharmaceuticals Corp | Sintesis de sales de bis(tio-hidrazida amida). |
JP2009504740A (ja) | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | ビス(チオ−ヒドラジドアミド)製剤 |
KR100724935B1 (ko) * | 2005-09-15 | 2007-06-04 | 삼성전자주식회사 | 컨텐츠 보호를 위한 개체 간 연동 방법 및 장치, 그리고 그시스템 |
EP2034996A2 (de) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Hsp90-aktivität modulierende triazolverbindungen |
US20080226588A1 (en) * | 2006-08-21 | 2008-09-18 | Mcleod Matthew | Treating melanoma with bis(thiohydrazide amides) |
US20100068174A1 (en) | 2006-08-21 | 2010-03-18 | Synta Pharmaceuticals Corp. | Combination with bis (thiohydrazide amides) for treating cancer |
US20080176828A1 (en) * | 2006-08-21 | 2008-07-24 | Martin Williams | Treating melanoma with BIS(THIOHYDRAZIDE AMIDES) |
WO2008024298A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for inhibiting angiogenesis |
TW200817371A (en) | 2006-08-21 | 2008-04-16 | Synta Pharmaceuticals Corp | Compounds for treating proliferative disorders |
TWI440632B (zh) | 2006-08-21 | 2014-06-11 | Synta Pharmaceuticals Corp | 用於治療增生性疾病的化合物 |
US20080057917A1 (en) * | 2006-08-30 | 2008-03-06 | Daniela Oria | Service availability update for a user having a prepaid account at a service provider capable of providing one or more services over a communications network |
AU2007290490B2 (en) * | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
TW200826926A (en) | 2006-09-11 | 2008-07-01 | Synta Pharmaceuticals Corp | Bis (thiohydrazide amides) formulation |
US20100093670A1 (en) | 2006-09-14 | 2010-04-15 | Yaming Wu | Compounds for the treatment of angiogenesis |
TW200829543A (en) | 2006-09-15 | 2008-07-16 | Synta Pharmaceuticals Corp | Purification of bis(thiohydrazide amides) |
KR100816561B1 (ko) * | 2006-11-24 | 2008-03-25 | 한국정보보호진흥원 | 외래 키를 이용한 모바일 멀티캐스트 키 관리 방법 |
US20090093538A1 (en) | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
US8093425B2 (en) | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
WO2009020631A2 (en) | 2007-08-07 | 2009-02-12 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
US8618170B2 (en) | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
EP2225201A2 (de) | 2007-11-28 | 2010-09-08 | Synta Pharmaceuticals Corp. | Polymorphe von n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazid) |
TW200940050A (en) | 2007-11-28 | 2009-10-01 | Synta Pharmaceuticals Corp | Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) |
-
2002
- 2002-07-09 TW TW091115202A patent/TWI297335B/zh not_active IP Right Cessation
- 2002-07-10 EP EP02752238A patent/EP1406870B1/de not_active Expired - Lifetime
- 2002-07-10 DE DE60234345T patent/DE60234345D1/de not_active Expired - Lifetime
- 2002-07-10 WO PCT/US2002/021714 patent/WO2003006428A1/en active Application Filing
- 2002-07-10 ES ES09004577T patent/ES2395141T3/es not_active Expired - Lifetime
- 2002-07-10 US US10/193,639 patent/US6762204B2/en not_active Expired - Lifetime
- 2002-07-10 AT AT09004577T patent/ATE523194T1/de not_active IP Right Cessation
- 2002-07-10 KR KR1020047000331A patent/KR100991325B1/ko not_active IP Right Cessation
- 2002-07-10 EP EP09004577A patent/EP2100605B9/de not_active Expired - Lifetime
- 2002-07-10 JP JP2003512200A patent/JP4344234B2/ja not_active Expired - Fee Related
- 2002-07-10 CA CA2454120A patent/CA2454120C/en not_active Expired - Fee Related
- 2002-07-10 AU AU2002354641A patent/AU2002354641B2/en not_active Ceased
- 2002-07-10 IL IL15977202A patent/IL159772A0/xx active IP Right Grant
- 2002-07-10 NZ NZ530964A patent/NZ530964A/en not_active IP Right Cessation
- 2002-07-10 MX MXPA04000243A patent/MXPA04000243A/es active IP Right Grant
- 2002-07-10 BR BR0211228-0A patent/BR0211228A/pt not_active IP Right Cessation
- 2002-07-10 KR KR1020107011645A patent/KR101092139B1/ko not_active IP Right Cessation
- 2002-07-10 AT AT02752238T patent/ATE448199T1/de active
- 2002-07-10 CN CNB028177266A patent/CN1308302C/zh not_active Expired - Fee Related
-
2004
- 2004-01-08 IL IL159772A patent/IL159772A/en not_active IP Right Cessation
- 2004-01-09 IS IS7102A patent/IS2718B/is unknown
- 2004-01-09 NO NO20040096A patent/NO333230B1/no not_active IP Right Cessation
- 2004-02-09 ZA ZA2004/01054A patent/ZA200401054B/en unknown
- 2004-03-18 US US10/803,798 patent/US7001923B2/en not_active Expired - Fee Related
- 2004-04-29 HK HK04103017.9A patent/HK1060117A1/xx not_active IP Right Cessation
-
2005
- 2005-10-05 US US11/244,427 patent/US7368473B2/en not_active Expired - Fee Related
-
2008
- 2008-03-20 US US12/077,729 patent/US7750042B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159772A0 (en) | Taxol enhancer compounds | |
UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
TW200642685A (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
PL377821A1 (pl) | 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu | |
GB0119249D0 (en) | Organic compounds | |
MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
MY146279A (en) | Compounds affecting glucokinase | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
WO2005115470A3 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS | |
ATE450534T1 (de) | Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung | |
CA2386775A1 (en) | Drugs for the treatment of malignant tumours | |
AU2003263878A1 (en) | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | |
GB9305295D0 (en) | Therapeutic compounds | |
GB0109122D0 (en) | Novel compounds | |
NZ516290A (en) | Substituted phenoxyacetic acids | |
PL342614A1 (en) | Anticarcinogenic drugs | |
GEP20074058B (en) | 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
GEP20053617B (en) | Bridged Piperazine Derivatives | |
IL229594A (en) | Derived Lactone Derivatives, Pharmaceutical Compositions Containing Them and Their Uses in the Preparation of Medical Preparations for Cancer Treatment | |
FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
UA42733C2 (uk) | Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить | |
WO2003022280A3 (en) | 3-glyoxlylamideindoles for treating cancer | |
ATE363909T1 (de) | Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten | |
BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |